|Articles|October 29, 2020

Episode 68: Rocking Garage Biotech

Panna Sharma, CEO of Lantern Pharma, discusses garage biotech, what he’s learned from the culture, and how it might help transform certain areas of pharma, including innovation and pricing.

Panna Sharma, CEO of Lantern Pharma, discusses garage biotech, what he’s learned from the culture, and how it might help transform certain areas of pharma, including innovation and pricing.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.